Biohaven (BHVN) Cash & Equivalents (2021 - 2026)

Biohaven has disclosed Cash & Equivalents across 6 years of filings, most recently posting $273.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $273.1 million, up 177.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $273.1 million (up 177.47% YoY), and the FY2025 annual result was $230.0 million, up 131.97% from the prior year.
• Cash & Equivalents came in at $273.1 million for Q1 2026 at Biohaven, up from $230.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $273.1 million in Q1 2026 to a low of $23.2 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $147.6 million (2023), against an average of $147.6 million.
• Across the five-year window, Cash & Equivalents sank 85.99% in 2022 and jumped 536.01% in 2023, its largest moves.
• Biohaven's Cash & Equivalents stood at $204.9 million in 2022, then gained by 21.24% to $248.4 million in 2023, then tumbled by 60.09% to $99.1 million in 2024, then soared by 131.97% to $230.0 million in 2025, then rose by 18.75% to $273.1 million in 2026.
• The last three Cash & Equivalents figures came in at $273.1 million (Q1 2026), $230.0 million (Q4 2025), and $184.8 million (Q3 2025), per Business Quant data.